

Publicaties 2019 MS Centrum Amsterdam

1. Aarts, SABM, Seijkens, TTP, Kusters, PJH, van Tiel, CM, Reiche, ME, den Toom, M, Beckers, L, van Roomen, CPAA, de Winther, MPJ, Kooij, G & Lutgens, E 2019, 'Macrophage CD40-signaling drives experimental autoimmune encephalomyelitis' *Journal of Pathology*, vol. 247, no. 4, pp. 471-480. <https://doi.org/10.1002/path.5205>
2. Amiri, H, Brouwer, I, Kuijer, JPA, de Munck, JC, Barkhof, F & Vrenken, H 2019, 'Novel imaging phantom for accurate and robust measurement of brain atrophy rates using clinical MRI' *NeuroImage: Clinical*, vol. 21, 101667. <https://doi.org/10.1016/j.nicl.2019.101667>
3. Balk LJ, Coric D, Knier B, Zimmermann HG, Behbehani R, Alroughani R, Martinez-Lapiscina EH, Brandt AU, Sánchez-Dalmau B, Vidal-Jordana A, Albrecht P, Koska V, Havla J, Pisa M, Nolan RC, Leocani L, Paul F, Aktas O, Montalban X, Balcer LJ, Villoslada P, Outteryck O, Korn T, Petzold A; IMSVISUAL consortium. Retinal inner nuclear layer volume reflects inflammatory disease activity in multiple sclerosis; a longitudinal OCT study. *Mult Scler J Exp Transl Clin*. 2019 Sep 5;5(3):2055217319871582. doi: 10.1177/2055217319871582. eCollection 2019 Jul-Sep. PubMed PMID: 31523449; PubMed Central PMCID: PMC6728683.
4. Barkhof, F, Kappos, L, Wolinsky, JS, Li, DKB, Bar-Or, A, Hartung, H-P, Belachew, S, Han, J, Julian, L, Sauter, A, Napieralski, J, Koendgen, H & Hauser, SL 2019, 'Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis' *Neurology*, vol. 93, no. 19, pp. e1778-e1786. <https://doi.org/10.1212/WNL.0000000000008189>, <https://doi.org/10.1212/WNL.0000000000008189>
5. Bartel, F, Vrenken, H, van Herk, M, de Ruiter, M, Belderbos, J, Hulshof, J & de Munck, JC 2019, 'Fast Segmentation through surface fairing (FastSURF): A novel semi-automatic hippocampus segmentation method' *PLoS ONE*, vol. 14, no. 1, e0210641. <https://doi.org/10.1371/journal.pone.0210641>
6. Battaglini, M, Gentile, G, Luchetti, L, Giorgio, A, Vrenken, H, Barkhof, F, Cover, KS, Bakshi, R, Chu, R, Sormani, MP, Enzinger, C, Ropele, S, Ciccarelli, O, Wheeler-Kingshott, C, Yiannakas, M, Filippi, M, Rocca, MA, Preziosa, P, Gallo, A, Biseco, A, Palace, J, Kong, Y, Horakova, D, Vaneckova, M, Gasperini, C, Ruggieri, S, de Stefano, N & MAGNIMS Study Group 2019, 'Lifespan normative data on rates of brain volume changes' *Neurobiology of Aging*, vol. 81, pp. 30-37. <https://doi.org/10.1016/j.neurobiolaging.2019.05.010>
7. Beckerman, H, Heine, M, Van Den Akker, LE & De Groot, V 2019, 'The 2-minute walk test is not a valid method to determine aerobic capacity in persons with multiple sclerosis' *NeuroRehabilitation*, vol. 45, no. 2, pp. 239-245. <https://doi.org/10.3233/nre-192792>, <https://doi.org/10.3233/NRE-192792>
8. Beltrán, E, Gerdes, LA, Hansen, J, Flierl-Hecht, A, Krebs, S, Blum, H, Ertl-Wagner, B, Barkhof, F, Kümpfel, T, Hohlfeld, R & Dornmair, K 2019, 'Early adaptive immune activation detected in monozygotic twins with prodromal multiple sclerosis' *Journal of Clinical Investigation*, vol. 129, no. 11, pp. 4758-4768. <https://doi.org/10.1172/JCI128475>, <https://doi.org/10.1172/JCI128475>
9. Bendfeldt, K, Taschler, B, Gaetano, L, Madoerin, P, Kuster, P, Mueller-Lenke, N, Amann, M, Vrenken, H, Wottschel, V, Barkhof, F, Borgwardt, S, Klöppel, S, Wicklein, EM, Kappos, L, Edan, G, Freedman, MS, Montalbán, X, Hartung, HP, Pohl, C, Sandbrink, R, Sprenger, T, Radue, EW, Wuerfel, J & Nichols, TE 2019, 'MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry' *Brain Imaging and Behavior*, vol. 13, no. 5, pp. 1361-1374. <https://doi.org/10.1007/s11682-018-9942-9>

10. Blikman, LJM, van Meeteren, J, Twisk, JWR, de Laat, FAJ, de Groot, V, Beckerman, H, Stam, HJ, Bussmann, JBJ & TREFAMS-ACE Study Group 2019, 'Energy Conservation Management for People With Multiple Sclerosis-Related Fatigue: Who Benefits?' *The American journal of occupational therapy* : official publication of the American Occupational Therapy Association, vol. 73, no. 4. <https://doi.org/10.5014/ajot.2019.032474>
11. Braakhuis, HEM, Berger, MAM, van der Stok, GA, van Meeteren, J, de Groot, V, Beckerman, H, Bussmann, JBJ, de Groot, V, Beckerman, H, Malekzadeh, A, van den Akker, LE, Looijmans, M, Sanches, SA, Dekker, J, Collette, EH, van Oosten, BW, Teunissen, CE, Blankenstein, MA, Eijssen, ICJM, Rietberg, M, Heine, M, Verschuren, O, Kwakkel, G, Visser-Meily, JMA, van de Port, IGL, Lindeman, E, Blikman, LJM, van Meeteren, J, Bussmann, JBJ, Stam, HJ, Hintzen, RQ, Hacking, HGA, Hoogervorst, EL, Frequin, STFM, Knoop, H, de Jong, BA, Bleijenberg, G, de Laat, FAJ, Verhulsdonck, MC, van Munster, ETL, Oosterwijk, CJ & Aarts, GJ 2019, 'Three distinct physical behavior types in fatigued patients with multiple sclerosis' *Journal of NeuroEngineering and Rehabilitation*, vol. 16, no. 1, 105. <https://doi.org/10.1186/s12984-019-0573-1>, <https://doi.org/10.1186/s12984-019-0573-1>
12. Bridel, C, van Wieringen, WN, Zetterberg, H, Tijms, BM, Teunissen, CE, Alvarez-Cermeño, JC, Andreasson, U, Axelsson, M, Bäckström, DC, Bartos, A, Bjerke, M, Blennow, K, Boxer, A, Brundin, L, Burman, J, Christensen, T, Fialová, L, Forsgren, L, Frederiksen, JL, Gisslén, M, Gray, E, Gunnarsson, M, Hall, S, Hansson, O, Herbert, MK, Jakobsson, J, Jessen-Krut, J, Janelidze, S, Johannsson, G, Jonsson, M, Kappos, L, Khademi, M, Khalil, M, Kuhle, J, Landén, M, Leinonen, V, Logroscino, G, Lu, C-H, Lycke, J, Magdalinou, NK, Malaspina, A, Mattsson, N, Meeter, LH, Mehta, SR, Modvig, S, Olsson, T, Paterson, RW, Pérez-Santiago, J, Piehl, F, Pijnenburg, YAL, Pyykkö, OT, Ragnarsson, O, Rojas, JC, Romme Christensen, J, Sandberg, L, Scherling, CS, Schott, JM, Sellebjerg, FT, Simone, IL, Skillbäck, T, Stilund, M, Sundström, P, Svenningsson, A, Tortelli, R, Tortorella, C, Trentini, A, Troiano, M, Turner, MR, van Swieten, JC, Vågberg, M, Verbeek, MM, Villar, LM, Visser, PJ, Wallin, A, Weiss, A, Wikkelsø, C & Wild, EJ 2019, 'Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis' *JAMA Neurology*, vol. 76, no. 9, pp. 1035-1048. <https://doi.org/10.1001/jamaneurol.2019.1534>
13. Brownlee, WJ, Altmann, DR, Prados, F, Miszkiel, KA, Eshaghi, A, Gandini Wheeler-Kingshott, CAM, Barkhof, F & Ciccarelli, O 2019, 'Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis' *Brain*, vol. 142, no. 8, pp. 2276-2287. <https://doi.org/10.1093/brain/awz156>
14. Buck, D, Andlauer, TF, Igl, W, Wicklein, E-M, Mühlau, M, Weber, F, Köchert, K, Pohl, C, Arnason, B, Comi, G, Cook, S, Filippi, M, Hartung, H-P, Jeffery, D, Kappos, L, Barkhof, F, Edan, G, Freedman, MS, Montalbán, X, Müller-Myhsok, B, Hemmer, B & BEYOND and BENEFIT Study Groups 2019, 'Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials' *Multiple Sclerosis*, vol. 25, no. 4, pp. 565-573. <https://doi.org/10.1177/1352458518763089>
15. Chatterjee, M, Schild, D & Teunissen, C 2019, 'Contactins in the central nervous system: role in health and disease' *Neural regeneration research*, vol. 14, no. 2, pp. 206-216. <https://doi.org/10.4103/1673-5374.244776>, <https://doi.org/10.4103/1673-5374.244776>
16. Chrobok, NL, Bol, JGJM, Wilhelmus, MMM, Drukarch, B & van Dam, A-M 2019, 'Tissue Transglutaminase Appears in Monocytes and Macrophages but Not in Lymphocytes in White Matter Multiple Sclerosis Lesions' *Journal of Neuropathology and Experimental Neurology*, vol. 78, no. 6, pp. 492-500. <https://doi.org/10.1093/jnen/nlz030>
17. Chrzanowski, U, Bhattarai, S, Scheld, M, Clarner, T, Fallier-Becker, P, Beyer, C, Rohr, SO, Schmitz, C, Hochstrasser, T, Schweiger, F, Amor, S, Horn-Bochtler, A, Denecke, B, Nyamoya, S & Kipp, M 2019, 'Oligodendrocyte degeneration and concomitant microglia activation directs peripheral immune cells into the forebrain' *Neurochemistry International*, vol. 126, pp. 139-153. <https://doi.org/10.1016/j.neuint.2019.03.005>

18. Cotta Ramusino, M, Altomare, D, Bacchin, R, Ingala, S, Brà, C, Bonetti, M, Costa, A, Barkhof, F, Nicolosi, V, Festari, C, Frisoni, GB & Boccardi, M 2019, 'Medial temporal lobe atrophy and posterior atrophy scales normative values' *NeuroImage: Clinical*, vol. 24, 101936. <https://doi.org/10.1016/j.nicl.2019.101936>
19. das Nair, R, de Groot, V & Freeman, J 2019, 'Beyond current research practice: Methodological considerations in MS rehabilitation research (is designing the perfect rehabilitation trial the Holy Grail or a Gordian knot?)' *Multiple Sclerosis Journal*, vol. 25, no. 10, pp. 1337-1347. <https://doi.org/10.1177/1352458519858271>
20. de Groot, V 2019, 'There is an urgent need for palliative care specialists in MS - Commentary' *Multiple Sclerosis Journal*, vol. 25, no. 13, pp. 1713-1714. <https://doi.org/10.1177/1352458519864935>
21. Dekker, I, Eijlers, AJC, Popescu, V, Balk, LJ, Vrenken, H, Wattjes, MP, Uitdehaag, BMJ, Killestein, J, Geurts, JJG, Barkhof, F & Schoonheim, MM 2019, 'Predicting clinical progression in multiple sclerosis after 6 and 12 years' *European Journal of Neurology*, vol. 26, no. 6, pp. 893-902. <https://doi.org/10.1111/ene.13904>
22. Dekker, I, Leurs, CE, Hagens, MHJ, van Kempen, ZLE, Kleerekooper, I, Lissenberg-Witte, BI, Barkhof, F, Uitdehaag, BMJ, Balk, LJ, Wattjes, MP & Killestein, J 2019, 'Long-term disease activity and disability progression in relapsing-remitting multiple sclerosis patients on natalizumab' *Multiple Sclerosis and Related Disorders*, vol. 33, pp. 82-87. <https://doi.org/10.1016/j.msard.2019.05.017>
23. de Kleermaeker, FGCM, Uitdehaag, BMJ, van Oosten, BW & van Munster, CEP 2019, 'Paroxysmale hypothermie bij multiple sclerose' *Nederlands Tijdschrift voor Geneeskunde*, vol. 163, no. 4, D3116.
24. Derada Troletti, C, Fontijn, RD, Gowing, E, Charabati, M, van Het Hof, B, Didouh, I, van der Pol, SMA, Geerts, D, Prat, A, van Horsen, J, Kooij, G & de Vries, HE 2019, 'Inflammation-induced endothelial to mesenchymal transition promotes brain endothelial cell dysfunction and occurs during multiple sclerosis pathophysiology' *Cell Death and Disease*, vol. 10, no. 2, 45. <https://doi.org/10.1038/s41419-018-1294-2>, <https://doi.org/10.1038/s41419-018-1294-2>
25. de Vries-Knoppert, WA, Baaijen, JC & Petzold, A 2019, 'Patterns of retrograde axonal degeneration in the visual system' *Brain*, vol. 142, no. 9, pp. 2775-2786. <https://doi.org/10.1093/brain/awz221>
26. de Wit NM, den Hoedt S, Martinez-Martinez P, Rozemuller AJ, Mulder MT, de Vries HE. Astrocytic ceramide as possible indicator of neuroinflammation. *J Neuroinflammation*. 2019 Feb 25;16(1):48. doi: 10.1186/s12974-019-1436-1.
27. de Wind, A, van der Beek, AJ, Boezeman, EJ, Swenneker, R, Anema, JR, de Boer, AGEM, Beckerman, H, Hoving, JL, Nieuwenhuijsen, K, Scharn, M, Stam, M, Terwee, CB, Frings-Dresen, MHW & Tamminga, SJ 2019, 'A qualitative study investigating the meaning of participation to improve the measurement of this construct' *Quality of Life Research*, vol. 28, no. 8, pp. 2233-2246. <https://doi.org/10.1007/s11136-019-02179-9>
28. Doesburg, D, Vennegoor, A, Uitdehaag, BMJ & van Oosten, BW 2019, 'High work absence around time of diagnosis of multiple sclerosis is associated with fatigue and relapse rate' *Multiple Sclerosis and Related Disorders*, vol. 31, pp. 32-37. <https://doi.org/10.1016/j.msard.2019.03.011>
29. Douw, L, van Dellen, E, Gouw, AA, Griffa, A, de Haan, W, van den Heuvel, M, Hillebrand, A, van Mieghem, P, Nissen, IA, Otte, WM, Reijmer, YD, Schoonheim, MM, Senden, M, van Straaten, ECW, Tijms, BM, Tewarie, P & Stam, CJ 2019, 'The road ahead in clinical network neuroscience' *Network Neuroscience*, vol. 3, no. 4, pp. 969-993. https://doi.org/10.1162/netn_a_00103

30. Eijlers, AJC, Wink, AM, Meijer, KA, Douw, L, Geurts, JJG & Schoonheim, MM 2019, 'Functional Network Dynamics on Functional MRI: A Primer on an Emerging Frontier in Neuroscience' *Radiology*, vol. 292, no. 2, pp. 460-463. <https://doi.org/10.1148/radiol.2019194009>
31. Eijlers, AJC, Wink, AM, Meijer, KA, Douw, L, Geurts, JJG & Schoonheim, MM 2019, 'Reduced Network Dynamics on Functional MRI Signals Cognitive Impairment in Multiple Sclerosis' *Radiology*, vol. 292, no. 2, pp. 449-457. <https://doi.org/10.1148/radiol.2019182623>
32. Eijlers, AJC, Dekker, I, Steenwijk, MD, Meijer, KA, Hulst, HE, Pouwels, PJW, Uitdehaag, BMJ, Barkhof, F, Vrenken, H, Schoonheim, MM & Geurts, JJG 2019, 'Cortical atrophy accelerates as cognitive decline worsens in multiple sclerosis' *Neurology*, vol. 93, no. 14, pp. e1348-e1359. <https://doi.org/10.1212/WNL.0000000000008198>
33. Elliott, C, Wolinsky, JS, Hauser, SL, Kappos, L, Barkhof, F, Bernasconi, C, Wei, W, Belachew, S & Arnold, DL 2019, 'Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions' *Multiple Sclerosis*, vol. 25, no. 14, pp. 1915-1925. <https://doi.org/10.1177/1352458518814117>
34. Elliott, C, Belachew, S, Wolinsky, JS, Hauser, SL, Kappos, L, Barkhof, F, Bernasconi, C, Fecker, J, Model, F, Wei, W & Arnold, DL 2019, 'Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis' *Brain*, vol. 142, no. 9, pp. 2787-2799. <https://doi.org/10.1093/brain/awz212>
35. Eshaghi, A, Kievit, RA, Prados, F, Sudre, CH, Nicholas, J, Cardoso, MJ, Chan, D, Nicholas, R, Ourselin, S, Greenwood, J, Thompson, AJ, Alexander, DC, Barkhof, F, Chataway, J & Ciccarelli, O 2019, 'Applying causal models to explore the mechanism of action of simvastatin in progressive multiple sclerosis' *Proceedings of the National Academy of Sciences of the United States of America*, vol. 166, no. 22, pp. 11020-11027. <https://doi.org/10.1073/pnas.1818978116>
36. Espitia Pinzon, N, van Mierlo, H, de Jonge, JC, Brevé, JJP, Bol, JGJM, Drukarch, B, van Dam, A-M & Baron, W 2019, 'Tissue transglutaminase promotes early differentiation of oligodendrocyte progenitor cells' *Frontiers in Cellular Neuroscience*, vol. 13, 281. <https://doi.org/10.3389/fncel.2019.00281>
37. Filippi, M, Preziosa, P, Banwell, BL, Barkhof, F, Ciccarelli, O, De Stefano, N, Geurts, JJG, Paul, F, Reich, DS, Toosy, AT, Traboulsee, A, Wattjes, MP, Yousry, TA, Gass, A, Lubetzki, C, Weinshenker, BG & Rocca, MA 2019, 'Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines' *Brain : a journal of neurology*, vol. 142, no. 7, pp. 1858-1875. <https://doi.org/10.1093/brain/awz144>
38. Filippi, M, Brück, W, Chard, D, Fazekas, F, Geurts, JJG, Enzinger, C, Hametner, S, Kuhlmann, T, Preziosa, P, Rovira, À, Schmierer, K, Stadelmann, C, Rocca, MA & Attendees of the Correlation between Pathological and MRI findings in MS workshop 2019, 'Association between pathological and MRI findings in multiple sclerosis' *The Lancet Neurology*, vol. 18, no. 2, pp. 198-210. [https://doi.org/10.1016/S1474-4422\(18\)30451-4](https://doi.org/10.1016/S1474-4422(18)30451-4)
39. Gasperini, C, Prosperini, L, Tintoré, M, Sormani, MP, Filippi, M, Rio, J, Palace, J, Rocca, MA, Ciccarelli, O, Barkhof, F, Sastre-Garriga, J, Vrenken, H, Frederiksen, JL, Yousry, TA, Enzinger, C, Rovira, A, Kappos, L, Pozzilli, C, Montalban, X & de Stefano, N 2019, 'Unraveling treatment response in multiple sclerosis: A clinical and MRI challenge' *Neurology*, vol. 92, no. 4, pp. 180-192. <https://doi.org/10.1212/WNL.0000000000006810>
40. Goldman MD, LaRocca NG, Rudick RA, Hudson LD, Chin PS, Francis GS, Jacobs A, Kapoor R, Matthews PM, Mowry EM, Balcer LJ, Panzara M, Phillips G, Uitdehaag BMJ, Cohen JA; Multiple Sclerosis Outcome Assessments Consortium. Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial data. *Neurology*. 2019 Nov 19;93(21):e1921-e1931. doi: 10.1212/WNL.0000000000008519. Epub 2019 Oct 22. PubMed PMID: 31641014; PubMed Central PMCID: PMC6885577.

41. Heine, M, Richards, R, Geurtz, B, Los, F, Rietberg, M, Harlaar, J, Gerrits, K, Beckerman, H & de Groot, V 2019, 'Preliminary effectiveness of a sequential exercise intervention on gait function in ambulant patients with multiple sclerosis – A pilot study' *Clinical Biomechanics*, vol. 62, pp. 1-6. <https://doi.org/10.1016/j.clinbiomech.2018.12.012>
42. Heinen, R, Steenwijk, MD, Barkhof, F, Biesbroek, JM, van der Flier, WM, Kuijf, HJ, Prins, ND, Vrenken, H, Biessels, GJ, de Bresser, J & TRACE-VCI study group 2019, 'Performance of five automated white matter hyperintensity segmentation methods in a multicenter dataset' *Scientific Reports*, vol. 9, no. 1, 16742. <https://doi.org/10.1038/s41598-019-52966-0>
43. Hupperts, R, Smolders, J, Vieth, R, Holmøy, T, Marhardt, K, Schlupe, M, Killestein, J, Barkhof, F, Beelke, M, Grimaldi, LME & SOLAR Study Group 2019, 'Randomized trial of daily high-dose vitamin D3 in patients with RRMS receiving subcutaneous interferon B-1a' *Neurology*, vol. 93, no. 20, pp. e1906-e1916. <https://doi.org/10.1212/WNL.0000000000008445>
44. Ilarregui, JM, Kooij, G, Rodríguez, E, van der Pol, SMA, Koning, N, Kalay, H, van der Horst, JC, van Vliet, SJ, García-Vallejo, JJ, de Vries, HE & van Kooyk, Y 2019, 'Macrophage galactose-type lectin (MGL) is induced on M2 microglia and participates in the resolution phase of autoimmune neuroinflammation' *Journal of Neuroinflammation*, vol. 16, no. 1, 130. <https://doi.org/10.1186/s12974-019-1522-4>, <https://doi.org/10.1186/s12974-019-1522-4>
45. International Multiple Sclerosis Genetics Consortium. Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk. *Cell*. 2019 Jun 27;178(1):262. doi: 10.1016/j.cell.2019.06.016. Erratum in: *Cell*. 2020 Jan 23;180(2):403. PubMed PMID: 31251915; PubMed Central PMCID: PMC6602362.
46. Jonkman, LE, Kenkhuis, B, Geurts, JJG & van de Berg, WDJ 2019, 'Post-Mortem MRI and Histopathology in Neurologic Disease: A Translational Approach' *Neuroscience Bulletin*, vol. 35, no. 2, pp. 229-243. <https://doi.org/10.1007/s12264-019-00342-3>
47. Kamermans, A, Planting, KE, Jalink, K, van Horssen, J & de Vries, HE 2019, 'Reactive astrocytes in multiple sclerosis impair neuronal outgrowth through TRPM7-mediated chondroitin sulfate proteoglycan production' *GLIA*, vol. 67, no. 1, pp. 68-77. <https://doi.org/10.1002/glia.23526>
48. Kamermans A, Verhoeven T, van Het Hof B, Koning JJ, Borghuis L, Witte M, van Horssen J, de Vries HE, Rijnsburger M. Setmelanotide, a Novel, Selective Melanocortin Receptor-4 Agonist Exerts Anti-inflammatory Actions in Astrocytes and Promotes an Anti-inflammatory Macrophage Phenotype. *Front Immunol*. 2019 Oct 4;10:2312. doi: 10.3389/fimmu.2019.02312. eCollection 2019. PubMed PMID: 31636637; PubMed Central PMCID: PMC6788433.
49. Kamermans, A, Rijnsburger, M, Chakraborty, A, van der Pol, S, de Vries, HE & van Horssen, J 2019, 'Reduced angiopoietin-like 4 expression in multiple sclerosis lesions facilitates lipid uptake by phagocytes via modulation of lipoprotein-lipase activity' *Frontiers in Immunology*, vol. 10, no. MAY, 950. <https://doi.org/10.3389/fimmu.2019.00950>
50. Kanber, B, Nachev, P, Barkhof, F, Calvi, A, Cardoso, J, Cortese, R, Prados, F, Sudre, CH, Tur, C, Ourselin, S & Ciccarelli, O 2019, 'High-dimensional detection of imaging response to treatment in multiple sclerosis' *NPJ digital medicine*, vol. 2, pp. 49. <https://doi.org/10.1038/s41746-019-0127-8>
51. Kanber B, Nachev P, Barkhof F, Calvi A, Cardoso J, Cortese R, Prados F, Sudre CH, Tur C, Ourselin S, Ciccarelli O. High-dimensional detection of imaging response to treatment in multiple sclerosis. *NPJ Digit Med*. 2019 Jun 10;2:49. doi: 10.1038/s41746-019-0127-8. eCollection 2019. Erratum in: *NPJ Digit Med*. 2019 Jul 16;2:66. PubMed PMID: 31304395; PubMed Central PMCID: PMC6556513.

52. Kanhai, KMS, Nij Bijvank, JA, Wagenaar, YL, Klaassen, ES, Lim, K, Bergheanu, SC, Petzold, A, Verma, A, Hesterman, J, Wattjes, MP, Uitdehaag, BMJ, van Rijn, LJ & Groeneveld, GJ 2019, 'Treatment of internuclear ophthalmoparesis in multiple sclerosis with fampridine: A randomized double-blind, placebo-controlled cross-over trial' *CNS Neuroscience and Therapeutics*, vol. 25, no. 6, pp. 697-703. <https://doi.org/10.1111/cns.13096>
53. Kiljan, S, Meijer, KA, Steenwijk, MD, Pouwels, PJW, Schoonheim, MM, Schenk, GJ, Geurts, JJG & Douw, L 2019, 'Structural network topology relates to tissue properties in multiple sclerosis' *Journal of Neurology*, vol. 266, no. 1, pp. 212-222. <https://doi.org/10.1007/s00415-018-9130-2>
54. Kiljan, S, Prins, M, Baselmans, BM, Bol, JGJM, Schenk, GJ & van Dam, A-M 2019, 'Enhanced GABAergic immunoreactivity in hippocampal neurons and astroglia of multiple sclerosis patients' *Journal of Neuropathology and Experimental Neurology*, vol. 78, no. 6, pp. 480-491. <https://doi.org/10.1093/jnen/nlz028>
55. Killestein, J & van Oosten, B 2019, 'Emerging safety issues in alemtuzumab-treated MS patients' *Multiple Sclerosis Journal*, vol. 25, no. 9, pp. 1206-1208. <https://doi.org/10.1177/1352458519851219>
56. Killestein, J & Reder, AT 2019, 'Dimethyl fumarate-induced changes in the MS lymphocyte repertoire: No need for subset monitoring' *Neurology*, vol. 92, no. 15, pp. 696-697. <https://doi.org/10.1212/WNL.00000000000007255>
57. Leurs, CE, Lopes Pinheiro, MA, Wierdsma, L, den Hoedt, S, Mulder, MT, Eijlers, AJC, Schoonheim, MM, Balk, LJ, Uitdehaag, BMJ, Killestein, J & de Vries, HE 2019, 'Acid sphingomyelinase: No potential as a biomarker for multiple sclerosis' *Multiple Sclerosis and Related Disorders*, vol. 28, pp. 44-49. <https://doi.org/10.1016/j.msard.2018.11.024>
58. Liu, Y, Dong, D, Zhang, L, Zang, Y, Duan, Y, Qiu, X, Huang, J, Dong, H, Barkhof, F, Hu, C, Fang, M, Tian, J & Li, K 2019, 'Radiomics in multiple sclerosis and neuromyelitis optica spectrum disorder' *European Radiology*, vol. 29, no. 9, pp. 4670-4677. <https://doi.org/10.1007/s00330-019-06026-w>
59. Loonstra, FC, van Rossum, JA, van Kempen, ZLE, Rispens, T, Uitdehaag, BMJ & Killestein, J 2019, 'Infusion-related events during natalizumab: no need for post-infusion monitoring' *Multiple Sclerosis Journal*, vol. 25, pp. 26-26.
60. Loonstra, FC, Verberk, IMW, Wijburg, MT, Wattjes, MP, Teunissen, CE, van Oosten, BW, Uitdehaag, BMJ, Killestein, J & van Kempen, ZLE 2019, 'Serum neurofilaments as candidate biomarkers of natalizumab associated progressive multifocal leukoencephalopathy' *Annals of Neurology*, vol. 86, no. 2, pp. 322-324. <https://doi.org/10.1002/ana.25523>
61. Mahmoodi M, Amiri H, Ayoobi F, Rahmani M, Taghipour Z, Ghavamabadi RT, Jafarzadeh A, Sankian M. Carvacrol ameliorates experimental autoimmune encephalomyelitis through modulating pro- and anti-inflammatory cytokines. *Life Sci.* 2019 Feb 15;219:257-263. doi: 10.1016/j.lfs.2018.11.051. Epub 2018 Nov 23
62. Malekzadeh, A, Leurs, C, van Wieringen, W, Steenwijk, MD, Schoonheim, MM, Amann, M, Naegelin, Y, Kuhle, J, Killestein, J & Teunissen, CE 2019, 'Plasma proteome in multiple sclerosis disease progression' *Annals of Clinical and Translational Neurology*, vol. 6, no. 9, pp. 1582-1594. <https://doi.org/10.1002/acn3.771>, <https://doi.org/10.1002/acn3.771>
63. Meijer, KA, Steenwijk, MD, Douw, L, Schoonheim, MM & Geurts, JJG 2019, 'Long-range connections are more severely damaged and relevant for cognition in multiple sclerosis' *Brain : a journal of neurology*, vol. 143, no. 1, pp. 150-160. <https://doi.org/10.1093/brain/awz355>
64. Meneghette, NS, de Carvalho, JER & Petzold, A 2019, 'A 30 s test for quantitative assessment of a relative afferent pupillary defect (RAPD): the infrared pupillary asymmetry (IPA)' *Journal of Neurology*, vol. 266, no. 4, pp. 969-974. <https://doi.org/10.1007/s00415-019-09223-1>

65. Moccia, M, Prados, F, Filippi, M, Rocca, MA, Valsasina, P, Brownlee, WJ, Zecca, C, Gallo, A, Rovira, A, Gass, A, Palace, J, Lukas, C, Vrenken, H, Ourselin, S, Gandini Wheeler-Kingshott, CAM, Ciccarelli, O, Barkhof, F & MAGNIMS Study Group 2019, 'Longitudinal spinal cord atrophy in multiple sclerosis using the generalized boundary shift integral' *Annals of Neurology*, vol. 86, no. 5, pp. 704-713. <https://doi.org/10.1002/ana.25571>
66. Naegelin Y, Naegelin P, von Felten S, Lorscheider J, Sonder J, Uitdehaag BMJ, Scotti B, Zecca C, Gobbi C, Kappos L, Derfuss T. Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis. *JAMA Neurol*. 2019 Mar 1;76(3):274-281. doi:10.1001/jamaneurol.2018.4239. PubMed PMID: 30615019; PubMed Central PMCID: PMC6439730.
67. Nij Bijvank, JA, Petzold, A, Coric, D, Stevie Tan, H, Uitdehaag, BMJ, Balk, LJ & van Rijn, LJ 2019, 'Quantification of visual fixation in multiple sclerosis' *Investigative Ophthalmology and Visual Science*, vol. 60, no. 5, pp. 1372-1383. <https://doi.org/10.1167/iovs.18-26096>
68. Nij Bijvank, JA, van Rijn, LJ, Balk, LJ, Tan, HS, Uitdehaag, BMJ & Petzold, A 2019, 'Diagnosing and quantifying a common deficit in multiple sclerosis: Internuclear ophthalmoplegia' *Neurology*, vol. 92, no. 20, pp. e2299-e2308. <https://doi.org/10.1212/WNL.0000000000007499>
69. Nij Bijvank, JA, van Rijn, LJ, Kamminga, M, Tan, HS, Uitdehaag, BMJ, Petzold, A & Balk, LJ 2019, 'Saccadic fatigability in the oculomotor system' *Journal of the Neurological Sciences*, vol. 402, pp. 167-174. <https://doi.org/10.1016/j.jns.2019.05.024>
70. Nolan-Kenney, RC, Liu, M, Akhand, O, Calabresi, PA, Paul, F, Petzold, A, Balk, L, Brandt, AU, Martínez-Lapiscina, EH, Saidha, S, Villoslada, P, Al-Hassan, AA, Behbehani, R, Frohman, EM, Frohman, T, Havla, J, Hemmer, B, Jiang, H, Knier, B, Korn, T, Leocani, L, Papadopoulou, A, Pisa, M, Zimmermann, H, Galetta, SL, Balcer, LJ & on behalf of the International Multiple Sclerosis Visual System Consortium 2019, 'Optimal intereye difference thresholds by optical coherence tomography in multiple sclerosis: An international study' *Annals of Neurology*, vol. 85, no. 5, pp. 618-629. <https://doi.org/10.1002/ana.25462>
71. Nutma, E, Willison, H, Martino, G & Amor, S 2019, 'Neuroimmunology - the past, present and future' *Clinical and Experimental Immunology*, vol. 197, no. 3, pp. 278-293. <https://doi.org/10.1111/cei.13279>
72. Nutma, E, Stephenson, JA, Gorter, RP, de Bruin, J, Boucherie, DM, Donat, CK, Breur, M, van der Valk, P, Matthews, PM, Owen, DR & Amor, S 2019, 'A quantitative neuropathological assessment of translocator protein expression in multiple sclerosis' *Brain : a journal of neurology*, vol. 142, no. 11, pp. 3440-3455. <https://doi.org/10.1093/brain/awz287>
73. Petzold, A, Woodhall, M, Khaleeli, Z, Tobin, WO, Pittock, SJ, Weinshenker, BG, Vincent, A, Waters, P & Plant, GT 2019, 'Aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies in immune-mediated optic neuritis at long-term follow-up' *Journal of Neurology, Neurosurgery and Psychiatry*, vol. 90, no. 9, pp. 1021-1026. <https://doi.org/10.1136/jnnp-2019-320493>
74. Petzold, A, Braithwaite, T, Oosten, BV, Balk, L, Martinez-Lapiscina, EH, Wheeler, R, Wiegnerinck, N, Waters, C & Plant, GT 2019, 'Case for a new corticosteroid treatment trial in optic neuritis: review of updated evidence' *Journal of Neurology, Neurosurgery and Psychiatry*. <https://doi.org/10.1136/jnnp-2019-321653>
75. Preziosa, P, Kiljan, S, Steenwijk, MD, Meani, A, van de Berg, WDJ, Schenk, GJ, Rocca, MA, Filippi, M, Geurts, JJG & Jonkman, LE 2019, 'Axonal degeneration as substrate of fractional anisotropy abnormalities in multiple sclerosis cortex' *Brain*, vol. 142, no. 7, pp. 1921-1937. <https://doi.org/10.1093/brain/awz143>

76. Preziosa, P, Kiljan, S, Steenwijk, MD, Meani, A, Van de Berg, WD, Schenk, G, Rocca, MA, Filippi, M, Geurts, J & Jonkman, LE 2019, 'Axonal degeneration as substrate of fractional anisotropy abnormalities in Multiple sclerosis cortex' *European Journal of Neurology*, vol. 26, pp. 107-107.
77. Preziosa, P, Kiljan, S, Steenwijk, MD, Meani, A, van de Berg, W, Schenk, G, Rocca, M, Filippi, M, Geurts, JJG & Jonkman, L 2019, 'Demyelination, Inflammation and Axonal Loss Explain Different Patterns of Fractional Anisotropy Abnormalities in MS Cortical Normal Appearing Gray Matter and Lesions' *Neurology*, vol. 92, no. 15.
78. Preziosa, P, Kiljan, S, Jonkman, L, van de Berg, W, Schenk, G, Rocca, M, Filippi, M, Geurts, JJG & Steenwijk, MD 2019, 'Local GM Demyelination and Remote Microstructural Damage in Connected WM Tracts both Contribute to Cortical Neurodegeneration in MS' *Neurology*, vol. 92, no. 15.
79. Preziosa, P, Kiljan, S, Steenwijk, MD, Meani, A, van de Berg, W, Schenk, G, Rocca, M, Filippi, M, Geurts, JJG & Jonkman, L 2019, 'Demyelination, Inflammation and Axonal Loss Explain Different Patterns of Fractional Anisotropy Abnormalities in MS Cortical Normal Appearing Gray Matter and Lesions (P5.2-024)' *Neurology*, vol. 92, no. 15 Supplement, pp. P5.2-024.
80. Rietberg MB, van Wegen EE. *Clinimetrics: The Neurological Fatigue Index for Multiple Sclerosis*. *J Physiother*. 2019 Oct;65(4):241. doi: 10.1016/j.jphys.2019.07.003.
81. Rimkus, CM, Schoonheim, MM, Steenwijk, MD, Vrenken, H, Eijlers, AJ, Killestein, J, Wattjes, MP, Leite, CC, Barkhof, F & Tijms, BM 2019, 'Gray matter networks and cognitive impairment in multiple sclerosis' *Multiple Sclerosis*, vol. 25, no. 3, pp. 382-391. <https://doi.org/10.1177/1352458517751650>
82. Rocca, MA, Valsasina, P, Meani, A, Gobbi, C, Zecca, C, Rovira, À, Montalban, X, Kearney, H, Ciccarelli, O, Matthews, L, Palace, J, Gallo, A, Bisecco, A, Gass, A, Eisele, P, Lukas, C, Bellenberg, B, Barkhof, F, Vrenken, H, Preziosa, P, Comi, G, Filippi, M & MAGNIMS Study Group 2019, 'Clinically relevant cranio-caudal patterns of cervical cord atrophy evolution in MS' *Neurology*, vol. 93, no. 20, pp. e1852-e1866. <https://doi.org/10.1212/WNL.0000000000008466>
83. Schmierer, K, Champion, T, Sinclair, A, van Hecke, W, Matthews, PM & Wattjes, MP 2019, 'Commentary: Towards a standard MRI protocol for multiple sclerosis across the UK' *British Journal of Radiology*, vol. 92, no. 1101, 20180926. <https://doi.org/10.1259/bjr.20180926>
84. Schoonheim, MM & Geurts, JJG 2019, 'What Causes Deep Gray Matter Atrophy in Multiple Sclerosis?' *American Journal of Neuroradiology*, vol. 40, no. 1, pp. 107-108. <https://doi.org/10.3174/ajnr.A5942>
85. Schoonheim, MM, Jonkman, LE, Eijlers, AJ, Meijer, KA, Killestein, J & Geurts, JJ 2019, 'Long-term natalizumab treatment is associated with a reduction in lesional white matter levels of myo-inositol, a biomarker of gliotic activity' *European Journal of Neurology*, vol. 26, pp. 858-858.
86. Schwenkenbecher P, Wurster U, Konen FF, Gingele S, Sühs KW, Wattjes MP, Stangel M, Skripuletz T. Impact of the McDonald Criteria 2017 on Early Diagnosis of Relapsing-Remitting Multiple Sclerosis. *Front Neurol*. 2019 Mar 15;10:188. doi: 10.3389/fneur.2019.00188. eCollection 2019. Review. PubMed PMID: 30930829; PubMed Central PMCID: PMC6428717
87. Sinnecker, T, Clarke, MA, Meier, D, Enzinger, C, Calabrese, M, De Stefano, N, Pitiot, A, Giorgio, A, Schoonheim, MM, Paul, F, Pawlak, MA, Schmidt, R, Kappos, L, Montalban, X, Rovira, À, Evangelou, N, Wuerfel, J & MAGNIMS Study Group 2019, 'Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis' *JAMA Neurology*, vol. 76. <https://doi.org/10.1001/jamaneurol.2019.2478>

88. ten Brinke, A, Claessen, I, van Kempen, ZLE, Killestein, J & Rispens, T 2019, 'Pharmacodynamic assessment of cell-bound natalizumab on PBMC samples stored in liquid nitrogen' *Journal of Immunological Methods*, vol. 473. <https://doi.org/10.1016/j.jim.2019.07.004>
89. Thompson, AJ, Antel, J, Carroll, WB & Geurts, J 2019, 'MSJ 2019 - Editorial comment' *Multiple Sclerosis Journal*, vol. 25, no. 1, pp. 4-5. <https://doi.org/10.1177/1352458518819096>
90. van Beek JJW, van Wegen EEH, Bol CD, Rietberg MB, Kamm CP, Vanbellinghen T. Tablet App Based Dexterity Training in Multiple Sclerosis (TAD-MS): Research Protocol of a Randomized Controlled Trial. *Front Neurol*. 2019 Feb 11;10:61. doi: 10.3389/fneur.2019.00061. eCollection 2019. PubMed PMID: 30804879; PubMed Central PMCID: PMC6378288.
91. van der Hiele, K, Hoogervorst, ELJ & Hulst, HE 2019, 'De onzichtbare last van cognitieve problemen bij multipele sclerose' *Nederlands Tijdschrift voor Geneeskunde*, vol. 163, no. 25.
92. van Geest, Q, Boeschoten, RE, Keijzer, MJ, Steenwijk, MD, Pouwels, PJ, Twisk, JW, Smit, JH, Uitdehaag, BM, Geurts, JJ, van Oppen, P & Hulst, HE 2019, 'Fronto-limbic disconnection in patients with multiple sclerosis and depression' *Multiple Sclerosis*, vol. 25, pp. 715-726. <https://doi.org/10.1177/1352458518767051>
93. van Kempen, ZLE, van Rossum, JA, Doesburg, D, Claessen, I, de Vries, A, ten Brinke, A, van Oosten, BW, Rispens, T & Killestein, J 2019, 'Anti-natalizumab antibodies during 8 years of natalizumab treatment: effect on natalizumab concentration and α 4-integrin receptor saturation' *Journal of Neurology*, vol. 266, no. 7, pp. 1804-1805. <https://doi.org/10.1007/s00415-019-09327-8>
94. van Kempen, ZLE, Doesburg, D, Dekker, I, Lissenberg-Witte, BI, de Vries, A, Claessen, IA, Brinke, AT, Rispens, T & Killestein, J 2019, 'The natalizumab wearing-off effect: End of natalizumab cycle, recurrence of MS symptoms' *Neurology*, vol. 93, no. 17, pp. e1579-e1586. <https://doi.org/10.1212/WNL.0000000000008357>
95. van Langelaar J, Rijvers L, Janssen M, Wierenga-Wolf AF, Melief MJ, Siepman TA, de Vries HE, Unger PA, van Ham SM, Hintzen RQ, van Luijn MM. Induction of brain-infiltrating T-bet-expressing B cells in multiple sclerosis. *Ann Neurol*. 2019 Aug;86(2):264-278. doi: 10.1002/ana.25508. Epub 2019 Jun 19. PubMed PMID: 31136008; PubMed Central PMCID: PMC6771938.
96. van Munster CE, D'Souza M, Steinheimer S, Kamm CP, Burggraaff J, Diederich M, Kravalis K, Dorn J, Walsh L, Dahlke F, Kappos L, Uitdehaag BM. Tasks of activities of daily living (ADL) are more valuable than the classical neurological examination to assess upper extremity function and mobility in multiple sclerosis. *Mult Scler*. 2019 Oct;25(12):1673-1681. doi: 10.1177/1352458518796690. Epub 2018 Aug 31.
97. van Rossum, JA, Peters, MAD, van der Valk, P & de Jong, BA 2019, 'Severe cutaneous adverse event in a daclizumab-treated multiple sclerosis patient' *Multiple Sclerosis and Related Disorders*, vol. 34, pp. 38-40. <https://doi.org/10.1016/j.msard.2019.06.006>
98. van Rossum, JA, van Kempen, ZLE, Schilder, L, Lissenberg-Witte, BI, Uitdehaag, B & Killestein, J 2019, 'Abnormalities and erythroblasts in peripheral blood of multiple sclerosis patients treated with natalizumab' *Multiple Sclerosis and Related Disorders*, vol. 36, 101382. <https://doi.org/10.1016/j.msard.2019.101382>
99. van Rossum JA, Killestein J, Villar LM, Riskind PN, Freedman MS, Teunissen C. gMS-Classifier1 does not predict disability progression in multiple sclerosis. *Mult Scler*. 2019 Jun;25(7):1010-1011. doi: 10.1177/1352458518798048. Epub 2018 Aug 31. PMID:30168749

100. van Wageningen, TA, Vlaar, E, Kooij, G, Jongenelen, CAM, Geurts, JJG & van Dam, A-M 2019, 'Regulation of microglial TMEM119 and P2RY12 immunoreactivity in multiple sclerosis white and grey matter lesions is dependent on their inflammatory environment' *Acta Neuropathologica Communications*, vol. 7, no. 1, 206. <https://doi.org/10.1186/s40478-019-0850-z>
101. Vlot, MC, Boekel, L, Kragt, J, Killestein, J, van Amerongen, BM, de Jonge, R, Den Heijer, M & Heijboer, AC 2019, 'Multiple sclerosis patients show lower bioavailable 25(OH)D and 1,25(OH)2D, but no difference in ratio of 25(OH)D/24,25(OH)2D and FGF23 concentrations' *Nutrients*, vol. 11, no. 11, 2774. <https://doi.org/10.3390/nu11112774>
102. Weeda, MM, Middelkoop, SM, Steenwijk, MD, Daams, M, Amiri, H, Brouwer, I, Killestein, J, Uitdehaag, BMJ, Dekker, I, Lukas, C, Bellenberg, B, Barkhof, F, Pouwels, PJW & Vrenken, H 2019, 'Validation of mean upper cervical cord area (MUCCA) measurement techniques in multiple sclerosis (MS): High reproducibility and robustness to lesions, but large software and scanner effects' *NeuroImage: Clinical*, vol. 24, 101962. <https://doi.org/10.1016/j.nicl.2019.101962>, <https://doi.org/10.1016/j.nicl.2019.101962>
103. Weeda, MM, Brouwer, I, de Vos, ML, de Vries, MS, Barkhof, F, Pouwels, PJW & Vrenken, H 2019, 'Comparing lesion segmentation methods in multiple sclerosis: Input from one manually delineated subject is sufficient for accurate lesion segmentation' *NeuroImage: Clinical*, vol. 24, 102074. <https://doi.org/10.1016/j.nicl.2019.102074>
104. Wetzels, S, Vanmierlo, T, Scheijen, JLJM, van Horsen, J, Amor, S, Somers, V, Schalkwijk, CG, Hendriks, JJA & Wouters, K 2019, 'Methylglyoxal-Derived Advanced Glycation Endproducts Accumulate in Multiple Sclerosis Lesions' *Frontiers in Immunology*, vol. 10, pp. 855. <https://doi.org/10.3389/fimmu.2019.00855>
105. Wijburg, MT, Warnke, C, Barkhof, F, Uitdehaag, BMJ, Killestein, J & Wattjes, MP 2019, 'Performance of PML diagnostic criteria in natalizumab-associated PML: data from the Dutch-Belgian cohort' *Journal of Neurology, Neurosurgery and Psychiatry*, vol. 90, no. 1, pp. 44-46. <https://doi.org/10.1136/jnnp-2018-318261>
106. Wottschel, V, Chard, DT, Enzinger, C, Filippi, M, Frederiksen, JL, Gasperini, C, Giorgio, A, Rocca, MA, Rovira, A, de Stefano, N, Tintoré, M, Alexander, DC, Barkhof, F, Ciccarelli, O & MAGNIMS study group and the EuroPOND consortium 2019, 'SVM recursive feature elimination analyses of structural brain MRI predicts near-term relapses in patients with clinically isolated syndromes suggestive of multiple sclerosis' *NeuroImage: Clinical*, vol. 24, 102011. <https://doi.org/10.1016/j.nicl.2019.102011>
107. Wouters E, de Wit NM, Vanmol J, van der Pol SMA, van Het Hof B, Sommer D, Loix M, Geerts D, Gustafsson JA, Steffensen KR, Vanmierlo T, Bogie JFJ, Hendriks JJA, de Vries HE. Liver X Receptor Alpha Is Important in Maintaining Blood-Brain Barrier Function. *Front Immunol*. 2019 Jul 31;10:1811. doi: 10.3389/fimmu.2019.01811. eCollection 2019. PubMed PMID: 31417573; PubMed Central PMCID: PMC6685401.

Algemeen

1. van der Valk, P 2019, 'Specialisatie versus generalisme in de pathologie' Nederlands Tijdschrift voor Geneeskunde, vol. 163, no. 20, D3585.

Abstracts

1. Beckerman, H, Heine, M, van den Akker, LE & de Groot, V 2019, 'The 2-minute walk test is not a valid method to determine aerobic capacity in persons with Multiple Sclerosis' Multiple Sclerosis Journal, vol. 25, no. 7, pp. 1043-1044.
2. Beckerman, H, Eken, M, Richards, R, van der Krogt, M, Gerrits, K, Rietberg, M, Heine, M & de Groot, V 2019, 'Quantifying muscle fatigue during walking in people with Multiple Sclerosis' Multiple Sclerosis Journal, vol. 25, no. 7, pp. 1043-1043.
3. Beckerman, H & de Groot, V 2019, 'Severity And Progression Of Cognitive Deficits In Newly Diagnosed Patients With Multiple Sclerosis: A 10-Year Follow-Up' Multiple Sclerosis Journal, vol. 25, no. 8, pp. NP12-NP13.
4. Boon, BDC, Pouwels, PJW, Jonkman, LE, Keijzer, MJ, Preziosa, P, de Berg, WDJV, Geurts, JJG, Scheltens, P, Barkhof, F, Rozemuller, AJM, Bouwman, FH & Steenwijk, MD 2019, 'Can post-mortem MRI be used as a proxy for in-vivo?' Multiple Sclerosis Journal, vol. 25, pp. 123-123.
5. Bouman, PM, Steenwijk, MD, Barkhof, F, Jonkman, LE & Geurts, JJG 2019, 'The optimal MRI technique for detecting cortical demyelination in multiple sclerosis: post-mortem validation of all so far suggested sequences' Multiple Sclerosis Journal, vol. 25, pp. 456-457.
6. Dekker, I, Ruet, A, Strik, M, Hulst, HE, Wattjes, MP, Barkhof, F, Uitdehaag, BMJ, Killestein, J, Geurts, JJG & Schoonheim, MM 2019, 'Specific cerebellar atrophy patterns can distinguish physical disability and cognitive impairment in MS' Multiple Sclerosis Journal, vol. 25, no. 8, pp. NP24-NP25.
7. Dekker, I, Ruet, A, Strik, M, Hulst, HE, Wattjes, MP, Barkhof, F, Uitdehaag, BMJ, Killestein, J, Geurts, JJG & Schoonheim, MM 2019, 'Specific cerebellar atrophy patterns in cross-sectional and longitudinal physical disability and cognitive impairment in multiple sclerosis' Multiple Sclerosis Journal, vol. 25, pp. 461-461.
8. Dekker, I, Schoonheim, MM, Venkatraghavan, V, Eijlers, AJC, Brouwer, I, Wattjes, MP, Wink, AM, Geurts, JJG, Uitdehaag, BMJ, Oxtoby, NP, Vrenken, H, Killestein, J, Barkhof, F & Wottschel, V 2019, 'Temporal ordering of multimodal biomarker abnormality in multiple sclerosis' Multiple Sclerosis Journal, vol. 25, pp. 461-462.
9. Huiskamp, M, de Jong, BA, Stalman, EW, Steenwijk, MD, Nauta, IM, de Geus-Driessen, S, Reuling, IEW, Vrenken, H, de Groot, V, Klein, M, Uitdehaag, BMJ, Geurts, JJG, Schoonheim, MM & Hulst, HE 2019, 'Thalamic volume as a measure to discriminate between subjective and objective cognitive complaints in MS: towards clinical application?' Multiple Sclerosis Journal, vol. 25, no. 8, pp. NP29-NP30.
10. Nauta, IM, Kulik, SD, Breedts, LC, Eijlers, AJC, Strijbis, EMM, Bertens, D, Tewartie, P, Hillebrand, A, Stam, CJ, Douw, L, Geurts, JJG, Uitdehaag, BMJ, de Jong, BA & Schoonheim, MM 2019, 'Functional brain network organization predicts cognitive decline in multiple sclerosis: a longitudinal magnetoencephalography study' Multiple Sclerosis Journal, vol. 25, no. 8, pp. NP9-NP10.
11. Kulik, SD, Nauta, IM, Lith, BDWT, Strijbis, EEM, Tewartie, P, Douw, L, Hillebrand, A, Stam, CJ, Geurts, JJG, de Jong, BA & Schoonheim, MM 2019, 'Functional imaging biomarkers of cognitive impairment in multiple sclerosis: a resting-state magnetoencephalography study' Multiple Sclerosis Journal, vol. 25, no. 8, pp. NP27-NP27.

12. Loonstra, FC, Verberk, IMW, Wijburg, MT, Wattjes, MP, Teunissen, CE, van Oosten, BW, Uitdehaag, BMJ, Killestein, J & van Kempen, ZLE 2019, 'Serum neurofilaments as candidate biomarkers of natalizumab-associated PML' *Multiple Sclerosis Journal*, vol. 25, pp. 284-284.
13. ten Thije-de Boer, M, de Groot, V & Beckerman, H 2019, 'The diagnostic value of the single leg heel rise-test compared to ankle push-off insufficiency shown by 2D gait analysis in MS patients' *Multiple Sclerosis Journal*, vol. 25, no. 7, pp. 1036-1036.
14. Weeda, MM, Pruis, IJ, Brouwer, I, Bellenberg, B, Schneider, R, Lukas, C, Barkhof, F, Vrenken, H & Pouwels, PJW 2019, 'Thalamus atrophy progresses faster in subjects with early MS who have more damage in the connected white matter and who show increasing disability over time' *Multiple Sclerosis Journal*, vol. 25, pp. 689-690.